144 related articles for article (PubMed ID: 17929115)
1. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Aoki T; Nishikawa R; Mizutani T; Nojima K; Mishima K; Adachi J; Matsutani M
Int J Clin Oncol; 2007 Oct; 12(5):341-9. PubMed ID: 17929115
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Riccardi A; Mazzarella G; Cefalo G; Garrè ML; Massimino M; Barone C; Sandri A; Ridola V; Ruggiero A; Mastrangelo S; Lazzareschi I; Caldarelli M; Maira G; Madon E; Riccardi R
Cancer Chemother Pharmacol; 2003 Dec; 52(6):459-64. PubMed ID: 13680160
[TBL] [Abstract][Full Text] [Related]
3. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
[TBL] [Abstract][Full Text] [Related]
4. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Reid JM; Stevens DC; Rubin J; Ames MM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
10. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
Beale P; Judson I; Moore S; Statkevich P; Marco A; Cutler DL; Reidenberg P; Brada M
Cancer Chemother Pharmacol; 1999; 44(5):389-94. PubMed ID: 10501912
[TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Ostermann S; Csajka C; Buclin T; Leyvraz S; Lejeune F; Decosterd LA; Stupp R
Clin Cancer Res; 2004 Jun; 10(11):3728-36. PubMed ID: 15173079
[TBL] [Abstract][Full Text] [Related]
12. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
[TBL] [Abstract][Full Text] [Related]
15. [Temozolomide in the treatment of recurrent malignant glioma].
Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
[TBL] [Abstract][Full Text] [Related]
16. Disposition and pharmacokinetics of temozolomide in rat.
Reyderman L; Statkevich P; Thonoor CM; Patrick J; Batra VK; Wirth M
Xenobiotica; 2004 May; 34(5):487-500. PubMed ID: 15370964
[TBL] [Abstract][Full Text] [Related]
17. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
Kim HK; Lin CC; Parker D; Veals J; Lim J; Likhari P; Statkevich P; Marco A; Nomeir AA
J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):225-33. PubMed ID: 9448080
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
Diez BD; Statkevich P; Zhu Y; Abutarif MA; Xuan F; Kantesaria B; Cutler D; Cantillon M; Schwarz M; Pallotta MG; Ottaviano FH
Cancer Chemother Pharmacol; 2010 Mar; 65(4):727-34. PubMed ID: 19641919
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.
Rajkumar SV; Reid JM; Novotny PJ; Safgren SL; Scheithauer BW; Johnson PS; Nair S; Morton RF; Hatfield AK; Krook JE; Ames MM; Buckner JC;
J Neurooncol; 2000 Sep; 49(3):255-61. PubMed ID: 11212905
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal
Hu C; Lin Q; Liu C; Liu J; Chen X; Li X; Zhao G; Zhang L
Cancer Chemother Pharmacol; 2020 Dec; 86(6):793-801. PubMed ID: 33089408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
